Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study

Trial Profile

Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Hypertriglyceridaemia; Low HDL cholesterol
  • Focus Pharmacodynamics
  • Acronyms EZEmRNA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Apr 2016 Status changed from recruiting to completed.
    • 31 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top